We recently published a list of Jim Cramer Discussed These 10 NASDAQ 100 Stocks Recently. In this article, we are going to ...

This was the stock's second consecutive day of losses.

The stock's fall snapped a two-day winning streak.

As part of the agreement, Sanofi will provide Alloy with upfront license fees and near-term preclinical milestone payments up ...

Shares of the battered biotech Vir Biotechnology were up more than 70% on Wednesday, as the company reported its first ...

Shares of Solid Biosciences (NASDAQ:SLDB) jumped 11% post-market after the company said the FDA had cleared an ...

Analysis of Biogen's stock performance in 2024, focusing on sales struggles, financial health, and valuation. Read more here.

Biogen (BIIB) announced the appointment of Adam Feire, Ph.D., as Head of Business Development and External Innovation. Feire reports to Adam ...

According to Benzinga Pro, Biogen's peer group average for short interest as a percentage of float is 5.09%, which means the company has less short interest than most of its peers. Did you know that ...

Truist analyst Srikripa Devarakonda lowered the firm’s price target on Biogen (BIIB) to $220 from $302 and keeps a Buy rating on the shares as ...

NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2025 of $0.22 per Class A ...

Scribe Therapeutics, co-founded by Jennifer Doudna, is reducing staff, the latest layoffs among companies focused on CRISPR ...